Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Completed · Phase 1
Conditions studied: Neoplasms
In brief
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
Key facts
- Study ID
- NCT05712889
- Run by
- Vincerx Pharma, Inc.
- People needed
- 29
- Starts
- 2023-01-24
- Expected to finish
- 2024-10-10
- Last updated by the study team
- 2024-11-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult patients aged >/=18 years, able to provide informed consent and willing to comply with all study procedures.
- Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies. Refer to NCCN guidelines of each respective histology for guidance. Starting with Amendment 3, this study will focus enrollment on the following cancers:
- Biliary tract cancers Breast cancer Cervical cancer Endometrial carcinoma Gastric cancer/gastroesophageal junction adenocarcinoma Nonsmall cell lung cancer Ovarian cancer/fallopian tube cancer/primary peritoneal cancer Pancreatic adenocarcinoma Small cell lung cancer Urothelial cancer
- Adequate bone marrow, liver, and renal functions.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
You may not qualify if…
- Subjects who have new or progressive brain or meningeal or spinal metastases.
- Clinically significant cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.
- Major surgery or significant trauma within 4 weeks before the first dose of study drug.
- Medical history of chronic obstructive pulmonary disease (COPD) and other respiratory disorders.
Where it is running
- Honor Health — Scottsdale, Arizona, United States
- NEXT Austin — Austin, Texas, United States
- NEXT Oncology San Antonio — San Antonio, Texas, United States
- Macquarie University — Macquarie Park, New South Wales, Australia
- ICON Brisbane — Brisbane, Queensland, Australia
- ICON Adelaide — Adelaide, Southern Australia, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.